225 related articles for article (PubMed ID: 12381228)
1. Extended-release methylphenidate (Ritalin LA).
Lyseng-Williamson KA; Keating GM
Drugs; 2002; 62(15):2251-9; discussion 2260-1. PubMed ID: 12381228
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate (OROS formulation).
Keating GM; McClellan K; Jarvis B
CNS Drugs; 2001; 15(6):495-500; discussion 501-3. PubMed ID: 11524026
[TBL] [Abstract][Full Text] [Related]
3. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
Robinson DM; Keating GM
Drugs; 2006; 66(5):661-8; discussion 669-70. PubMed ID: 16620143
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.
Lopez F; Silva R; Pestreich L; Muniz R
Paediatr Drugs; 2003; 5(8):545-55. PubMed ID: 12895137
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
Biederman J; Quinn D; Weiss M; Markabi S; Weidenman M; Edson K; Karlsson G; Pohlmann H; Wigal S
Paediatr Drugs; 2003; 5(12):833-41. PubMed ID: 14658924
[TBL] [Abstract][Full Text] [Related]
6. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.
Markowitz JS; Straughn AB; Patrick KS
Pharmacotherapy; 2003 Oct; 23(10):1281-99. PubMed ID: 14594346
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.
Maldonado R
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1001-14. PubMed ID: 23611637
[TBL] [Abstract][Full Text] [Related]
8. Dexmethylphenidate.
Keating GM; Figgitt DP
Drugs; 2002; 62(13):1899-904; discussion 1905-8. PubMed ID: 12215063
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
Anderson VR; Scott LJ
Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.
Döpfner M; Gerber WD; Banaschewski T; Breuer D; Freisleder FJ; Gerber-von Müller G; Günter M; Hässler F; Ose C; Rothenberger A; Schmeck K; Sinzig J; Stadler C; Uebel H; Lehmkuhl G
Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I93-101. PubMed ID: 15322960
[TBL] [Abstract][Full Text] [Related]
13. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
Childress AC; Sallee FR; Berry SA
Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
[TBL] [Abstract][Full Text] [Related]
14. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
McGough JJ; Pataki CS; Suddath R
Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
16. [Benefit of the extended-release methylphenidate formulations: a comparative study in childhood].
Favreau A; Deseille-Turlotte G; Brault F; Giraudeau B; Krier C; Barthez MA; Castelnau P
Arch Pediatr; 2006 May; 13(5):442-8. PubMed ID: 16597499
[TBL] [Abstract][Full Text] [Related]
17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
18. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.
Wolraich ML; Doffing MA
CNS Drugs; 2004; 18(4):243-50. PubMed ID: 15015904
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
